

## ASX RELEASE

27 November 2018



### CHANGE OF RESPIRI BOARD OF DIRECTORS

**Respiri Limited (ASX:RSH)** (“Respiri” or “the Company”) announces the appointments of Mr Ross Blair-Holt and Professor Bruce Thompson as Non-Executive Directors of the Company. Non-Executive Chairman Mr Mark Ziirsen and Non-Executive Directors, Mr Brendan Mason and Dr Thomas Duthy have each resigned to coincide with the new Directors’ appointment.

The Company is withdrawing resolutions 2, 3 and 5 from tomorrow’s Annual General Meeting agenda as the outgoing Directors do not seek re-election.

CEO and Director, Mario Gattino thanked Mr Mark Ziirsen, Mr Brendan Mason and Dr Thomas Duthy for their significant contribution and wished them well in future endeavours.

For **Ross Blair-Holt**, this is a welcome return to the Respiri Board at a time when his deep business and big company experience will be of considerable assistance as Respiri focuses on the market launch of wheezo™ in 2019.

Ross is a Director and CEO of all Bruce Mathieson Group private family companies, Director of ALH Group Pty Ltd, since 2004 and Chief Operating Officer 2004 – 2014. He is also a Director of Beovista Pty Ltd, an energy saving machine manufacturer and operator, and Director of GreyScan Pty Ltd, world’s first inorganic explosive detector, and Firefly Health Pty Ltd, non-invasive personal hypoglycaemic monitoring for Type 1 diabetics. Ross has a Bachelor of Commerce from the University of Melbourne and is Fellow, Certified Practising Accountants (FCPA).

**Professor Bruce Thompson** B.app.Sci, CRFS, FANZSRS, FThorSoc, FAPSR, PhD. currently serves as Chair of Respiri’s Australian Medical and Scientific Advisory Board. He is Head, Physiological Services at The Alfred Hospital, one of the largest lung function laboratories in Australia, Adjunct Professor, Central Clinical School, Monash University and will take up his new role as Dean, School of Health Sciences at Swinburne University of Technology in 2019.

Bruce is the President-elect of the Thoracic Society of Australia and New Zealand and is a member of a number of other professional associations including the Asia Pacific Society of Respiriology, American Thoracic Society, European Respiratory Society, National Health and Medical Research Council, Institute for Breathing and Sleep, Lung Health Promotion Centre, National Science Week and World Congress in Biomedical Engineering. Bruce has been the recipient of over \$34 million in competitive grants for research, has contributed to Government Policy Documents and is the author of numerous peer reviewed journal articles and official documents.

---End---

Contact:  
Mario Gattino  
CEO & Director  
+61 3 9653 9160

## **ABOUT RESPIRI LIMITED**

Respiri's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiri Limited's operations are based in Melbourne, Australia.

## **FORWARD LOOKING STATEMENTS**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.